ストックスクリーナーアプリを入手
1.37
1.48%
0.02
アフターアワーズ：
1.37
前日終値:
$1.35
開ける：
$1.38
24時間の取引高:
239.58K
Relative Volume:
0.15
時価総額：
$47.10M
収益：
-
当期純損益:
$-16.14M
株価収益率:
-2.537
EPS:
-0.54
ネットキャッシュフロー:
$-3.99M
1週間 パフォーマンス:
-7.43%
1か月 パフォーマンス:
-4.20%
6か月 パフォーマンス:
-22.16%
1年 パフォーマンス:
-70.66%
1日の値動き範囲:
$1.35
$1.42
1週間の範囲:
$1.34
$1.486
52週間の値動き範囲:
$1.12
$5.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
TELO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.37 | 46.41M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-21 | 開始されました | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc (TELO) 最新ニュース
Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationJuly 2025 PostEarnings & Community Driven Trade Alerts - Улправда
Can Telomir Pharmaceuticals Inc. stock sustain revenue growth2025 Growth vs Value & Daily Market Momentum Tracking - Улправда
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - ACCESS Newswire
Is Telomir Pharmaceuticals Inc. stock a top momentum playJuly 2025 Action & Accurate Buy Signal Alerts - Улправда
Telomir Pharmaceuticals Reports Positive IND-Enabling Study Results - TipRanks
TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death - MSN
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells - USA Today
Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells - Daily Commercial
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Telomir Pharmaceuticals Inc. stock attracts high net worth investorsTrade Signal Summary & Free Community Supported Trade Ideas - Newser
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Up 2.3% – Still a Buy? - Defense World
Telomir Pharmaceuticals announces new preclinical data on Telomir-1 - MSN
Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support - marketscreener.com
Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data - MSN
Telomir reports PSA reduction in prostate cancer cells with lead drug - Investing.com Nigeria
Telomir reports PSA reduction in prostate cancer cells with lead drug By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Reports Promising Preclinical Data - TipRanks
[8-K] Telomir Pharmaceuticals, Inc. Reports Material Event | TELO SEC FilingForm 8-K - Stock Titan
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells - Bluffton Today
Will Telomir Pharmaceuticals Bounce Back? - StocksToTrade
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025 - ts2.tech
Telomir stock surges after leukemia cell-killing data By Investing.com - Investing.com Nigeria
Telomir stock surges after leukemia cell-killing data - Investing.com UK
Telomir Pharma (NASDAQ: TELO) Telomir-1 Shows Preclinical HL60 Leukemia Activity - Stock Titan
Telomir Pharmaceuticals director Craig Eagle resigns from board By Investing.com - Investing.com Australia
Telomir Pharmaceuticals director Craig Eagle resigns from board - Investing.com
Telomir Pharmaceuticals Inc. Announces Resignation of Craig Eagle as Director, Effective on November 14, 2025 - MarketScreener
Telomir Pharmaceuticals’ Telomir-1 Shows Leukemia Efficacy - TipRanks
Telomir Pharmaceuticals, Inc. Announces Telomir-1 Kills Aggressive Human Leukemia Cells - marketscreener.com
How Telomir Pharmaceuticals Inc. stock performs after earnings2025 Market Overview & Precise Buy Zone Tips - newser.com
Does Telomir Pharmaceuticals Inc. stock trade at a discount to peersQuarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Will Telomir Pharmaceuticals Inc. bounce back from current supportMarket Activity Recap & Precise Buy Zone Tips - newser.com
Telomir Pharmaceuticals Inc (TELO) 財務データ
収益
当期純利益
現金流量
EPS
0.31%
0.33%
大文字化:
|
ボリューム (24 時間):